What is the clinical evidence from this study?

Study design: Other. Population: congestive heart failure. Intervention: exogenous atrial natriuretic peptide (ANP) vs. healthy dogs. Primary outcome: hemodynamic, renal, and hormonal variables.

What question did this study set out to answer?

To evaluate endogenous atrial natriuretic peptide secretion and assess hemodynamic, renal, and hormonal responsiveness to exogenous peptide infusions in experimental heart failure.

February 1, 1988CirculationOpen Access

Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects.

View Full Paper

Ask AI

Bookmark

Key result

Exogenous ANP infusion in dogs with heart failure caused a small reduction in mean arterial pressure but lacked the renal excretory effects seen in healthy dogs, suggesting an intracellular defect.

Why the study?

Does exogenous ANP infusion improve hemodynamic and renal parameters in a dog model of congestive heart failure compared to healthy dogs?

Population

Dog model of congestive heart failure induced by rapid right ventricular pacing, and healthy dogs

Comparison

Incremental infusions of exogenous atrial… vs Healthy dogs receiving the same ANP infusions

Design

Preclinical

Authors

GRGünter A.J. RieggerHeart Failure / Cardiomyopathy DEDietmar ElsnerKlinikum Passau EKEckhard P. KromerDélégation Paris 5

Discussion

Member takes

Implication

ANP shows limited benefit without renal effects in canine HF; hypothesis-generating for intracellular defects, leaves open human translation.

Key Points

To evaluate endogenous atrial natriuretic peptide secretion and assess hemodynamic, renal, and hormonal responsiveness to exogenous peptide infusions in experimental heart failure.
Induced congestive heart failure in dogs using rapid right ventricular pacing and monitored hemodynamics, cyclic guanosine monophosphate, and atrial cell ultrastructure.
Administered incremental intravenous infusions of exogenous atrial natriuretic peptide (0.01 to 0.3 µg/kg/min) to both healthy and heart failure dogs to compare systemic and renal responses.
Heart failure development elevated plasma atrial natriuretic peptide and cyclic guanosine monophosphate alongside prominent ultrastructural activation of atrial myoendocrine secretory apparatus.
In healthy dogs, exogenous peptide infusions reduced mean arterial pressure and cardiac output while markedly increasing urinary sodium, chloride, magnesium, calcium excretion, and glomerular filtration rate.
In dogs with heart failure, exogenous peptide induced only a minor blood pressure drop, failed to suppress renin, and showed a complete absence of renal excretory actions despite normal cyclic guanosine monophosphate generation.

Structured PICO

Does exogenous ANP infusion improve hemodynamic and renal parameters in a dog model of congestive heart failure compared to healthy dogs?

Population

Dog model of congestive heart failure induced by rapid right ventricular pacing, and healthy dogs

Intervention

Incremental infusions of exogenous atrial natriuretic peptide (ANP) at 0.01, 0.03, 0.1, 0.3, and 0.06 microgram/kg/min

Comparator

Healthy dogs receiving the same ANP infusions

Outcome

Hemodynamic, renal, and hormonal variables (including mean arterial pressure, cardiac output, stroke volume, right atrial pressure, urine flow, electrolyte excretion, renin, GFR, and c-GMP)surrogate

In a canine model of heart failure, the renal excretory effects of ANP are completely blunted despite normal c-GMP secretion, suggesting an intracellular defect in signal mediation.

Cite This Study

Riegger et al. (1988) studied congestive heart failure. exogenous atrial natriuretic peptide (ANP) vs. healthy dogs was evaluated on hemodynamic, renal, and hormonal variables. Exogenous ANP infusion in dogs with heart failure caused a small reduction in mean arterial pressure but lacked the renal excretory effects seen in healthy dogs, suggesting an intracellular defect.

synapsesocial.com/papers/6a0b9936faed69294fd0a2b6 https://doi.org/10.1161/01.cir.77.2.398

Topics

Heart failure HFrEF treatment

View Full Paper

Ask AI

Bookmark

Implication

ANP shows limited benefit without renal effects in canine HF; hypothesis-generating for intracellular defects, leaves open human translation.

Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects.

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects.

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider